Back to Search
Start Over
Dolutegravir: an exciting new kid on the block.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2014 Mar; Vol. 15 (4), pp. 573-82. Date of Electronic Publication: 2014 Jan 22. - Publication Year :
- 2014
-
Abstract
- Introduction: Dolutegravir is the first second-generation integrase inhibitor approved for the treatment of naïve as well as experienced HIV-infected individuals.<br />Areas Covered: Data from pharmacokinetics, efficacy, safety, tolerability and resistance are reviewed from in vitro studies, Phase II and III clinical trials published in PubMed (Dolutegravir; S/GSK1349572) or presented in international meetings.<br />Expert Opinion: Data from studies and clinical trials indicate that dolutegravir is safe, well tolerated and highly efficacious in the treatment of both antiretroviral-naïve and treatment-experienced patients and appears to have a higher genetic barrier to resistance than first-generation integrase inhibitors.
- Subjects :
- Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Resistance, Viral genetics
Genetic Therapy
HIV Infections enzymology
HIV Integrase chemistry
HIV Integrase genetics
HIV Integrase metabolism
HIV Integrase Inhibitors pharmacokinetics
Heterocyclic Compounds, 3-Ring pharmacokinetics
Humans
Mutation
Oxazines
Piperazines
Protein Conformation
Pyridones
HIV Infections drug therapy
HIV Integrase Inhibitors therapeutic use
Heterocyclic Compounds, 3-Ring therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 15
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 24446762
- Full Text :
- https://doi.org/10.1517/14656566.2014.868883